For the first time in my life, my stomach doesnt hurt every day, she said
Conclusions Both observational and mendelian randomization analyses showed a significantly lower risk of DR for patients treated with GLP-1 RAs, which calls for further studies to validate these findings
In May 2026, At the EASL Congress 2026, MetaVia presented promising late-breaking Phase 1 clinical trial results for DA-1726, an investigational dual GLP-1 and glucagon receptor agonist under development for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
By supporting the bodys detoxification process and protecting cells from damage, glutathione injections may improve skin clarity, minimize dark spots, and enhance overall radiance
doi:10.1016/s2213-8587(17)30092-x 5.Nauck MA, DAlessio DA